Medtronic® Attain Ability™ Model 4196 Lead - P080006
This is a brief overview of information related to FDA’s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for FDA’s approval.
Product Name: Medtronic® Attain Ability™ Model 4196 Lead
PMA Applicant: Medtronic, Inc.
Address: 8200 Coral Sea Street NE, Mounds View, MN 55112
Approval Date: April 7, 2009
Approval Letter: http://www.accessdata.fda.gov/cdrh_docs/pdf8/P080006a.pdf
What is it? The Medtronic® Attain Ability™ Model 4196 Lead (Model 4196) is a surgically implanted insulated wire that is designed to be used as part of a biventricular pacemaker system. The Model 4196 lead is designed to be implanted in a branch of the coronary vein that goes over the surface of the heart’s left ventricle. A small amount of steroid (dexamethasone acetate) at the tip is intended to reduce inflammation of the surrounding tissue. The other end of the lead connects to an implanted biventricular pacemaker or implantable cardioverter defibrillator (ICD), so signals and electrical impulses can be sent between that device and the left ventricle.
How does it work? In some heart-failure patients, the right and left sides of the heart may not contract together, at the same time. The Model 4196 lead, as part of a biventricular system, sends electrical impulses to the heart to promote simultaneous contraction of both ventricles.
When is it used? The Model 4196 lead is used with a compatible Medtronic cardiac resynchronization therapy (CRT) system to provide chronic pacing and sensing of the left ventricle. Additional leads in other heart chambers are used with the pacemaker to coordinate the entire heart’s action at a regular, appropriate rate.
What will it accomplish? The Model 4196, in conjunction with an implanted pacing device and other leads, helps the heart chambers pump more efficiently by coordinating the timing of contractions. This improved coordination may reduce the symptoms of heart failure and is called cardiac resynchronization therapy, or CRT.
When should it not be used? The Model 4196 should not be used in patients with blocked or inadequate blood vessels for placing leads, or in patients who cannot tolerate a single dose of dexamethasone acetate (232 µg).
Additional information: The Summary of Safety and Effectiveness and Labeling will be available online.